Stocks News

LAST PRICE
42.1300
TODAY'S CHANGE (%)
Trending Up0.0700 (0.1664%)

Bid / Lots
42.0300/ 6
Ask / Lots
42.2300/ 6
Open / Previous Close
41.9100 / 42.0600
Day Range
Low 41.0300
High 42.3900
52 Week Range
Low 8.7202
High 59.2300
Volume
77,686
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 21, 2024
- Harrow Says ImprimisRx Unit Wins Jury Verdict in Trademark Infringement Case, from 8:40AM ET on Thursday Nov 21, 2024 by MT Newswires
  8:40AM ET on Thursday Nov 21, 2024 by MT Newswires
  Companies Mentioned: HROW
  08:40 AM EST, 11/21/2024 (MT Newswires) -- Harrow (HROW) said Thursday that a California jury ruled in favor of its subsidiary ImprimisRx in a trademark infringement against OSRX and Ocular Science. The jury awarded $34.9 million in damages, which i...
- *DJ Harrow's ImprimisRx Subsidiary Receives $34.9M Unanimous Jury Verdict Award in Case Vs. OSRX Inc., from 7:03AM ET on Thursday Nov 21, 2024 by Dow Jones
  7:03AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: HROW
- Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc., from 7:00AM ET on Thursday Nov 21, 2024 by Dow Jones
  7:00AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: HROW
  
  Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
  
  Jury in Trademark Infringement Case Finds in Favor of ImprimisRx
Nov 20, 2024
- Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery, from 7:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
  7:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: HROW
  
  Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
Nov 15, 2024
- Harrow Announces Participation in Upcoming Investor Conferences, from 7:00AM ET on Friday Nov 15, 2024 by Dow Jones
  7:00AM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: HROW
  
  Harrow Announces Participation in Upcoming Investor Conferences
  NASHVILLE, Tenn.--(BUSINESS WIRE)--November 15, 2024--
  Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences:

Today
- Ocular Therapeutix(TM) to Participate in December Investor and Scientific Conferences, from 4 hours ago by Dow Jones
  4 hours ago by Dow Jones
  Companies Mentioned: OCUL
Nov 20, 2024
- Kiniksa Pharmaceuticals International Insider Sold Shares Worth $357,680, According to a Recent SEC Filing, from 4:43PM ET on Wednesday Nov 20, 2024 by MT Newswires
  4:43PM ET on Wednesday Nov 20, 2024 by MT Newswires
  Companies Mentioned: KNSA
Nov 15, 2024
- DJ Ocular Therapeutix Is Maintained at Buy by HC Wainwright & Co., from 7:11AM ET on Friday Nov 15, 2024 by Dow Jones
  7:11AM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: OCUL
Nov 14, 2024
- Ligand to Present at Stifel 2024 Healthcare Conference, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: LGND
- Ocular Therapeutix Q3 Net Loss Narrows as Revenue Increases, from 7:29AM ET on Thursday Nov 14, 2024 by MT Newswires
  7:29AM ET on Thursday Nov 14, 2024 by MT Newswires
  Companies Mentioned: OCUL
- -- Earnings Flash (OCUL) OCULAR THERAPEUTIX Reports Q3 Revenue $15.4M, from 7:10AM ET on Thursday Nov 14, 2024 by MT Newswires
  7:10AM ET on Thursday Nov 14, 2024 by MT Newswires
  Companies Mentioned: OCUL
- Ocular Therapeutix(TM) Reports Third Quarter 2024 Results and Business Highlights, from 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: OCUL
- *DJ Ocular Therapeutix 3Q Loss/Shr 22c >OCUL, from 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: OCUL
Nov 13, 2024
- Ocular Therapeutix(TM) to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV, from 7:30AM ET on Wednesday Nov 13, 2024 by Dow Jones
  7:30AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: OCUL
Nov 12, 2024
- Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
  4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: KNSA

Harrow Inc
NASDAQ:HROWUnited States

Search Criteria

Nov 21, 2024

Harrow Says ImprimisRx Unit Wins Jury Verdict in Trademark Infringement Case, from 8:40AM ET on Thursday Nov 21, 2024 by MT Newswires

*DJ Harrow's ImprimisRx Subsidiary Receives $34.9M Unanimous Jury Verdict Award in Case Vs. OSRX Inc., from 7:03AM ET on Thursday Nov 21, 2024 by Dow Jones

Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc., from 7:00AM ET on Thursday Nov 21, 2024 by Dow Jones

Nov 20, 2024

Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery, from 7:00AM ET on Wednesday Nov 20, 2024 by Dow Jones

Nov 15, 2024

Harrow Announces Participation in Upcoming Investor Conferences, from 7:00AM ET on Friday Nov 15, 2024 by Dow Jones

Peers Headlines

Today

Ocular Therapeutix(TM) to Participate in December Investor and Scientific Conferences, from 4 hours ago by Dow Jones

Nov 20, 2024

Kiniksa Pharmaceuticals International Insider Sold Shares Worth $357,680, According to a Recent SEC Filing, from 4:43PM ET on Wednesday Nov 20, 2024 by MT Newswires

Nov 15, 2024

DJ Ocular Therapeutix Is Maintained at Buy by HC Wainwright & Co., from 7:11AM ET on Friday Nov 15, 2024 by Dow Jones

Nov 14, 2024

Ligand to Present at Stifel 2024 Healthcare Conference, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones

Ocular Therapeutix Q3 Net Loss Narrows as Revenue Increases, from 7:29AM ET on Thursday Nov 14, 2024 by MT Newswires

-- Earnings Flash (OCUL) OCULAR THERAPEUTIX Reports Q3 Revenue $15.4M, from 7:10AM ET on Thursday Nov 14, 2024 by MT Newswires

Ocular Therapeutix(TM) Reports Third Quarter 2024 Results and Business Highlights, from 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones

*DJ Ocular Therapeutix 3Q Loss/Shr 22c >OCUL, from 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 13, 2024

Ocular Therapeutix(TM) to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV, from 7:30AM ET on Wednesday Nov 13, 2024 by Dow Jones

Nov 12, 2024

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones